256 related articles for article (PubMed ID: 10896235)
1. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
[TBL] [Abstract][Full Text] [Related]
2. Inherited prothrombotic risk factors in Turkish children with acute lymphoblastic leukemia: significance of concomitant genetic mutation.
Torun YA; Patiroglu T; Ozdemir MA; Ozkul Y; Ekici A; Karakukcu M
Clin Appl Thromb Hemost; 2012; 18(2):218-21. PubMed ID: 21873357
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Nowak-Göttl U; Heinecke A; von Kries R; Nürnberger W; Münchow N; Junker R
Thromb Res; 2001 Aug; 103(3):165-72. PubMed ID: 11672578
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
5. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Appel IM; Hop WC; Pieters R
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of thrombotic children with malignancy.
Unal S; Varan A; Yalçin B; Büyükpamukçu M; Gürgey A
Ann Hematol; 2005 Jun; 84(6):395-9. PubMed ID: 15735962
[TBL] [Abstract][Full Text] [Related]
8. Low rate of severe venous thromboses in children with ALL treatment according to COALL-92 and -97 protocol.
Mauz-Körholz C; Nürnberger W; Irsfeld H; Körholz D; Göbel U
Klin Padiatr; 1999; 211(4):215-7. PubMed ID: 10472553
[TBL] [Abstract][Full Text] [Related]
9. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
10. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
Giordano P; Molinari AC; Del Vecchio GC; Saracco P; Russo G; Altomare M; Perutelli P; Crescenzio N; Santoro N; Marchetti M; De Mattia D; Falanga A
Am J Hematol; 2010 May; 85(5):325-30. PubMed ID: 20425794
[TBL] [Abstract][Full Text] [Related]
12. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol.
Kirschke R; Nürnberger W; Eckhof-Donovan S; Nürnberger I; Göbel U
Klin Padiatr; 1998; 210(4):285-90. PubMed ID: 9743967
[TBL] [Abstract][Full Text] [Related]
13. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
14. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.
Nowak-Göttl U; Wermes C; Junker R; Koch HG; Schobess R; Fleischhack G; Schwabe D; Ehrenforth S
Blood; 1999 Mar; 93(5):1595-9. PubMed ID: 10029588
[TBL] [Abstract][Full Text] [Related]
16. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
Ziino O; Russo D; Orlando MA; Benigno V; Locatelli F; Aricò M
Med Pediatr Oncol; 2002 Jul; 39(1):32-4. PubMed ID: 12116076
[TBL] [Abstract][Full Text] [Related]
18. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
19. [Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols].
Sutor AH; Niemeyer C; Sauter S; Witt I; Kaufmehl K; Rombach A; Brandis M; Riehm H
Klin Padiatr; 1992; 204(4):264-73. PubMed ID: 1518263
[TBL] [Abstract][Full Text] [Related]
20. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
